Download PDF
TumorDiagnostik & Therapie 2002; 23(4): 137-144
DOI: 10.1055/s-2002-33856
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Therapie mit Docetaxel und Carboplatin bei Patienten mit fortgeschrittenem nicht-kleinzelligen Bronchialkarzinom (NSCLC) in der klinischen Praxis

Docetaxel/Carboplatin Combination Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in Daily Clinical RoutineA.  Reißig, A.  Klippstein, M.  Förster, C.  Kroegel
  • 1Pneumologie und Allergologie, Klinik für Innere Medizin IV, Friedrich-Schiller-Universität Jena
Herrn Prof. Dr. G. Stein zum 65. Geburtstag gewidmet.
Further Information

Publication History

Publication Date:
05 September 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Ziel der Studie war die Untersuchung der Wirksamkeit und Toxizität einer Kombination aus Docetaxel und Carboplatin als First- und Second-line-Chemotherapie bei Patienten mit fortgeschrittenem nicht-kleinzelligen Bronchialkarzinom in der täglichen klinischen Routine. Zwischen 10/1996 und 5/2001 erhielten 38 Patienten (10 Frauen, 28 Männer; medianes Alter 62 Jahre) mit histologisch bestätigtem nicht-kleinzelligen Bronchialkarzinom im Stadium III B (n = 9) und Stadium IV (n = 29) und einem Allgemeinzustand Grad 0 - 2 nach ECOG (Grad 0: n = 2; Grad 1: n = 27; Grad 2: n = 9) eine Kombinationschemotherapie aus Docetaxel und Carboplatin. Den ersten 12 Patienten wurden alle drei Wochen 100 mg/m2 Docetaxel, kombiniert mit Carboplatin 300 mg/m2, verabreicht. Die folgenden 26 Patienten erhielten alle drei Wochen 75 mg/m2 Docetaxel zusammen mit Carboplatin AUC 5. Für 32 Patienten (84,2 %) war es eine First-line-Chemotherapie. 5 Patienten wurden im Rahmen einer Second-line-Chemotherapie behandelt und ein Patient erhielt die Behandlung als Fourth-line-Chemotherapie. Insgesamt wurden 164 Zyklen verabreicht, im Median 4 Zyklen pro Patient. Histologisch lagen 17 Adenokarzinome (44,8 %), 12 Plattenepithelkarzinome (31,6 %), ein großzelliges Karzinom (2,6 %) und 8 nicht weiter differenzierbare nicht-kleinzellige Bronchialkarzinome (21 %) vor. Drei Patienten (7,9 %) wiesen eine partielle Remission (PR) auf. Ein stabiler Erkrankungszustand (SD) war bei 32 Patienten (84,2 %) zu verzeichnen. Drei Patienten (7,9 %) wiesen eine Progression (PD) auf. Gegenwärtig leben noch 7 Patienten. Die 1- und 2-JahresÜberlebensraten betragen 34,2 % bzw. 7,9 %. Das mediane Überleben liegt bei 237 Tagen (95 %-CI 228-434) und die mediane Zeit bis zur Progression beträgt 138 Tage (95 %-CI 144-318). Eine Leukozytopenie Grad 4 lag bei 7 Patienten (18,4 %) und Grad 3 bei 14 Patienten (36,8 %) vor. Es trat kein therapiebedingter Todesfall auf. Die Kombination aus Docetaxel (75 mg/m2) und Carboplatin (AUC 5) ist auch außerhalb von klinisch kontrollierten Studien eine wirksame und verträgliche First- und Second-line-Chemotherapie bei Patienten mit fortgeschrittenem nicht-kleinzelligen Bronchialkarzinom.

Abstract

The activity and toxicity of the combination of Docetaxel and Carboplatin as first- and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) were studied in daily clinical routine. Between 10/1996 and 05/2001, 38 patients (10 females, 28 males; median age 62 years) with histologically confirmed stage III B (n = 9) and IV (n = 29) NSCLC and with an ECOG performance status of PS 0 - 2 (PS 0: n = 2; PS 1: n = 27; PS 2: n = 9) were treated. The first 12 patients received Docetaxel (100 mg/m2) plus Carboplatin (300 mg/m2) and the following patients Docetaxel (75 mg/m2) plus Carboplatin (AUC 5). 32 patients (84.2 %) were treated with first-line chemotherapy, 5 patients with second- and one patient with fourth-line therapy. Cycles were repeated every three weeks to a maximum of 6 cycles. A total of 164 cycles was delivered with a median of 4 cycles per patient. Tumor histology was adenocarcinoma (17; 44.8 %), squamous cell (12; 31.6 %), large cell (1; 2.6 %) and other undifferentiated NSCLC (8; 21 %). Partial response (PR) was observed in three patients (7.9 %), stable disease (SD) in 32 patients (84.2 %) and progressive disease (PD) in three patients (7.9 %). 7 patients are still alive. Median survival was 237 days (228 - 434 days, 95 % CI), and median time to progression was 138 days (144 - 318 days, 95 % CI). The 1- and 2-year survival was 34.2 % and 7.9 %, respectively. Leucopenia grade 4 was observed in 7 patients (18.4 %), grade 3 in 15 patients (36.8 %). There was no treatment-related death. These results demonstrate that the combination chemotherapy with Docetaxel (75 mg/m2) and Carboplatin (AUC 5) is an active and feasible regimen as first- and second-line treatment of advanced NSCLC outside controlled clinical trials.

Schlüsselwörter

Fortgeschrittenes nicht-kleinzelliges Bronchialkarzinom - Docetaxel und Carboplatin - First-line-Therapie - Second-line-Therapie - Klinische Praxis

Key words

Advanced non small cell lung cancer - Docetaxel and Carboplatin combination chemotherapy - First- and second-line chemotherapy - Daily clinical routine

Literatur

  • 1 Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus best supportive care versus supportive care for patients with advanced non-small-cell lung cancer.  J Natl Cancer Inst. 2000;  92 1074-1080
    CrossrefPubMedGoogle Scholar
  • 2 Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advances non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.  Lung cancer. 1999;  24 17-24
    CrossrefPubMedGoogle Scholar
  • 3 Giannakakis T, Papadouris S, Ziras N, Kouroussis C, Mavroudis D, Kalbakis K, Kakolyris S, Agelaki S, Ziani D, Vakaloudi N, Papadakis E, Androulakis N, Souglakos J, Sarra E, Hatzidaki D, Georgoulias V. For the Greek Lung Cancer Cooperative Group. Phase I/II study of docetaxel (D) and carboplatin (CBDCA) as 1st line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). Preliminary restuls.  Proc Am Soc Clin Oncol. 1998;  17 486a
    PubMedGoogle Scholar
  • 4 Douillard J Y, Monnier A, Ibrahim N, Belli L, Sun X S, Soulas F, Boyer R, Berille J, Le Chevalier T. Preliminary report of a phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC).  Eur J Cancer. 1995;  31A (Suppl. 5) 228
    PubMedGoogle Scholar
  • 5 Mattson K, Saarinen A, Jekunen A. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.  Semin Oncol. 1997;  23 (14) S 14-5-S 14-8
    PubMedGoogle Scholar
  • 6 Ornstein D L, Nervi A M, Rigas J R. for the Thoracic Oncology Program . Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small cell lung cancer.  Annals of Oncology. 1999;  10 (Suppl. 5) 35-40
    PubMedGoogle Scholar
  • 7 Miller V A, Kris M G. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.  Semin Oncol. 2000;  27 (Suppl. 3) 3-10
    PubMedGoogle Scholar
  • 8 Belani C P. Docetaxel (Taxotere) in combination with platinum-based regimes in non-small cell lung cancer: Results and future developements.  Semin Oncol. 1999;  26 (Suppl. 10) 15-18
    PubMedGoogle Scholar
  • 9 Schütte W, Bork I, Wollschlager B, Schädlich S. Docetaxel (Taxotere) and carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC).  Ann Oncol. 1998;  9 (Suppl. 4) 90
    PubMedGoogle Scholar
  • 10 Capozzoli M J, Belani C P, Einzig A, Bonomi P, Dobbs T, Kozak C, Cohen L J. Multi-institutional phase II trial of Docetaxel and Carboplatin combination in patients with stage IIIR and IV non-small cell lung cancer.  Proc ASCO. 1998;  17 479 a
    PubMedGoogle Scholar
  • 11 Griesinger F, Kern W, Binder L, Hannemann P, Criee C P, Hemmerlein B, Dalichau H, Hess C F, Wörmann B, Schleyer E, Schmidberger H, Herse B, Hiddemann W. Outpatient Taxotere/Carboplatin (T/C) combination therapy in NSCLCL for induction in stage III B and palliation in stage IV.  Proc Am Soc Clin Oncol. 1998;  17 487a
    PubMedGoogle Scholar
  • 12 Millward M J, Bishop J, Lehnert M, Boyer M, Rischin D, Clarke S, Childs A, McCormack T, Wong J. Phase II trial of docetaxel and carboplatin in advanced non-small cell lung cancer (NSCLC).  Proc Am Soc Clin Oncol. 1999;  18 517a
    PubMedGoogle Scholar
  • 13 Arcenas A, Anderson A, Krasnow S. Docetaxel/carboplatin combination therapy for stage III B/IV non-small cell lung cancer (NSCLC).  Proc Am Soc Clin Oncol. 1999;  18 495 a
    PubMedGoogle Scholar
  • 14 Pestasides D, Aspropotamitis A, Halikia A, Visvikis A, Antoniou F, Kalantariou A, Batzios S, Karvounis N, Athanassiou A. Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small cell lung cancer: A phase II study.  Eur J Cancer. 1999;  35 (Suppl. 4) 263
    PubMedGoogle Scholar
  • 15 Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.  Semin Oncol. 2001;  28 (Suppl. 2) 10-14
    PubMedGoogle Scholar
  • 16 Belani C P, Einzig A, Bonomi P, Dobbs T, Kozak C, Cohen L, Capozzoli M J. Mulltiinstitutional phase II trial of docetaxel and carboplatin combination in patients with stage III B and IV non-small cell lung cancer.  Lung cancer. 1997;  18 16
    PubMedGoogle Scholar
  • 17 Oken M M, Creech R H, Tormey D C, Horton J, Davis T E, McFadden E T, Carbone P P. Toxicity and response criteria of the Eastern Cooperative Oncology Group.  Am J Clin Oncol. 1982;  5 649-655
    CrossrefPubMedGoogle Scholar
  • 18 Kaplan E L, Meier P. Nonparametric estimation from incomplete observations.  J Am Stat Assoc. 1958;  53 457-481
    CrossrefPubMedGoogle Scholar
  • 19 Souquet P J, Chauvin F, Boissel J P, Cellerino R, Cormier Y, Ganz P A, Kaasa S, Pater J L, Quoix E, Rapp E, Tumarello D, Williams J, Woods B L, Bernard J P. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis.  Lancet. 1993;  342 19-21
    CrossrefPubMedGoogle Scholar
  • 20 Non-Small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.  Br Med J. 1995;  311 800-909
    PubMedGoogle Scholar
  • 21 Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature.  Chest. 1994;  106 861-865
    CrossrefPubMedGoogle Scholar
  • 22 Shepherd F A, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of Docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with Platinum-based chemotherapy.  J Clin Oncol. 2000;  18 2095-2103
    CrossrefPubMedGoogle Scholar
  • 23 Fosella F V, DeVore R, Kerr R N, Crawford J, Natale R R, Dunphy F, Kalman L, Miller V, Lee J S, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. and the TAX 320 Non-Small Cell Lung Cancer Study Group . Randomized phase III trial od Docetaxel versus Vinorelbine or Ifosfamide in patients with advanced non-small cell lung cancer previously treated with Platinum-containing chemotherapy regimens.  J Clin Oncol. 2000;  18 2354-2362
    CrossrefPubMedGoogle Scholar
  • 24 Giannakakis T, Ziras N, Kakolyris S, Mavroudis D, Androulakis N, Agelaki S, Parashos M, Sarra E, Dimou T, Hatzidaki D, Vlachonikolis J, Georgoulias V. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.  Europ J Cancer. 2000;  36 742-747
    CrossrefPubMedGoogle Scholar
  • 25 Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fosella F, Kaukel E, Mattson K, Millward M, Kim Y S, Gamza F, Berille J, Belani C P. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer.  Proc Am Soc Clin Oncol. 2001;  20 1252
    PubMedGoogle Scholar
  • 26 Mattson K, Bosquee L, Dabouis G, Le Groumellec A, Pujol J L, Marien S, Stupp R, Douillard J Y, Brägas B, Berille J, Olivares R, Le Chevalier T. Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.  Lung Cancer. 2000;  29 205-216
    PubMedGoogle Scholar
  • 27 Schiller J H, Harrington D, Belani C P, Langner C, Sandler A, Krook J, Zhu J, Johnson D H. for the Eastern Cooperative Oncology Group . Comparison of four chemotherapy regimens for advanced non-small cell lung cancer.  N Engl J Med. 2002;  346 92-98
    CrossrefPubMedGoogle Scholar
  • 28 Fosella F V, Lee J S, Shin D M, Calayag M, Huber M, Perez-Soler R, Murphy W K, Lippmann S, Benner S, Glisson B, Chasen M, Hong W K, Raber M. Phase II study of Docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer.  J Clin Oncol. 1995;  13 645-651
    PubMedGoogle Scholar
  • 29 Miller V A, Rigas J R, Francis P A, Grant S C, Pisters K MW, Venkatraman E S, Woolley K, Heelan R T, Kris M G. Phase II-trial of a 75-mg/m2 dose of Docetaxel with Prednisone premedication for patients with advanced non-small cell lung cancer.  Cancer. 1995;  75 968-972
    PubMedGoogle Scholar
  • 30 Schütte W, Bork I, Wollschlager B, Schädlich S. Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer.  Clin Drug Invest. 2001;  21 161-168
    PubMedGoogle Scholar
  • 31 Francis P A, Rigas J R, Kris M G, Pisters K MW, Orazem J P, Woolley K J, Heelan R T. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer.  J Clin Oncol. 1994;  12 1232-1237
    PubMedGoogle Scholar

Dr. med. Angelika Reißig

Pneumologie und Allergologie, Klinik für Innere Medizin IV,
Friedrich-Schiller-Universität

Erlanger Allee 101

07747 Jena

Phone: + 49-3641-939625

Fax: + 49-3641-939326

Email: Angelika.Reissig@med.uni-jena.de

      >